<DOC>
	<DOC>NCT01036399</DOC>
	<brief_summary>Revlimid is a potent immunomodulatory analogue without the teratogenic effects, which has direct anti-tumor effects, anti-angiogenic and both anti-inflammatory and T-cell costimulatory properties. Both preclinical and clinical data indicate its efficacy solid tumor and multiple myeloma including advanced/refractory stages with its role in enhancing host antitumor immunity that provided the rationale to use in patients with PTCL.</brief_summary>
	<brief_title>Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patients with histologic diagnosis of PTCL according to the WHOREAL classification; Age &gt; 18 years; Relapsed (Â³1) or refractory to conventional chemotherapy/radiotherapy; Stage IIV according to the Ann Arbor staging System; Performance status &lt;2; Adequate bone marrow reserve: platelets &gt;50 x 10(9)/L, absolute neutrophil count (ANC) &gt; 1.0 x 10(9)/L, hemoglobin &gt;8 g/d; Normal renal and hepatic functions; Negative HIV, HCV, and HBV status; Informed consent prior to registration on study Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form. Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking lenalidomide). Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. Use of any other experimental drug or therapy within 28 days of baseline. Known hypersensitivity to thalidomide. The development of erythema if characterized by a desquamating rash while taking thalidomide or similar drugs. Any prior use of lenalidomide. Concurrent use of other anticancer agents or treatments. Known positive for HIV or infectious hepatitis, type A, B or C.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>PTCL</keyword>
</DOC>